Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$2.73 - $5.08 $1.1 Million - $2.04 Million
-401,410 Reduced 73.83%
142,274 $587,000
Q3 2022

Nov 14, 2022

BUY
$1.53 - $3.64 $831,836 - $1.98 Million
543,684 New
543,684 $1.74 Million

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $174M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Cvi Holdings, LLC Portfolio

Follow Cvi Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cvi Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cvi Holdings, LLC with notifications on news.